The biliary tract cancers (BTCs) industry is witnessing steady expansion driven by advancements in targeted therapies and diagnostic techniques. With increasing investments focused on oncology drug development and rising awareness about early diagnosis, the market dynamics are shifting towards personalized and value-based care solutions. This evolving landscape reflects significant...